- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Phase 3 PREVAIL Study Delivers Promising Results in Prostate Cancer Patients
The results of the Phase 3 Prevail Study on enzalutamide showed significant benefit to prostate cancer patients including delaying the progression of metastatic disease, reducing the risk of death and delaying the start of cytotoxic chemotherapy.
The results of the Phase 3 PREVAIL study on enzalutamide showed significant benefit to prostate cancer patients including delaying the progression of metastatic disease, reducing the risk of death and delaying the start of cytotoxic chemotherapy.
Enzalutamide did translate to significant overall survival to an unprecedented extent,” said Prof. Bertrand Tombal (BE) during the Late Breaking News segment of the concluding plenary session of the 29th Annual EAU Congress which ends today in Stockholm, Sweden.
Bertrand said the results of the main study and the European regional results of the phase 3 randomised PREVAIL study also has to be considered in a very rapidly changing treatment landscape when new prostate cancer drugs are emerging.
“Enzalutamide also has impact on other points such as time- to-PSA progression and has demonstrated a tolerability profile comparable to placebo,” he noted. “One of the clinical benefits is the ability to use this agent in second-line hormonal manipulation.”
Read the complete news report here: http://bit.ly/QayKhy
Source: EAU News
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
